Print this page
-
A Phase I Study to Evaluate the Safety of Naltrexone and Propranolol in Combination with Standard of Care Ipilimumab and Nivolumab in Patients with Advanced Melanoma.
Protocol: 092302Principal Investigator:
- Sarah Weiss MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Melanoma, Skin -
Understanding Sun Protection and Skin Examination Practices Among Hispanics.
Protocol: 132111Principal Investigator:
- Carolyn Heckman Ph.D. (Rutgers University)
Applicable Disease Sites: Melanoma, Skin -
Cutaneous Oncology Clinical Database and Biospecimen Bank
Protocol: 002233Principal Investigator:
- Sarah Weiss MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Melanoma, Skin -
NCI 10204 - A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
Protocol: 092305Principal Investigator:
- Sarah Weiss MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Melanoma, Skin -
A Phase 2 and Phase 3 Peri-Operative trial of Fianlimab and Cemiplimab Compared with Pembrolizumab in Patients with Resectable Stage III and IV Melanoma.
Protocol: 092303Principal Investigator:
- Adam Berger (Rutgers University)
Applicable Disease Sites: Melanoma, Skin -
Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma.
Protocol: 092202Principal Investigator:
- Adam Berger (Rutgers University)
Applicable Disease Sites: Melanoma, Skin